Targeting mitochondrial oxidative metabolism as an approach to treat heart failure

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 4, 2013, Pages 857-865

  Fillmore, Natasha ^a   Lopaschuk, Gary D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Carnitine palmitoyltransferase 1; Fatty acid oxidation; Glucose oxidation; Glycolysis; Heart failure; Mitochondria

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MALONYL COENZYME A DECARBOXYLASE; PHOSPHOTRANSFERASE INHIBITOR; PYRUVATE DEHYDROGENASE KINASE;

AEROBIC METABOLISM; CELL DIFFERENTIATION; CELL METABOLISM; ENERGY METABOLISM; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE CELL; HUMAN; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ENZYME INHIBITORS; FATTY ACIDS; GLUCOSE; HEART; HEART FAILURE; HUMANS; MITOCHONDRIA; MYOCYTES, CARDIAC; OXIDATIVE PHOSPHORYLATION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ADRENERGIC, BETA;

EID: 84875068490     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.08.014     Document Type: Review

References (143)

1. McMurray J.J.V., Pfeffer M.A. Heart failure. Lancet 2005, 365:1877-1889.
2. Lopaschuk G.D., Ussher J.R., Folmes C.D.L., Jaswal J.S., Stanley W.C. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 2010, 90:207-258.
3. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005, 85:1093-1129.
4. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., Oates J.A., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 2009, 53:e1-e90.
5. Peterson P.N., Rumsfeld J.S., Liang L., Hernandez A.F., Peterson E.D., Fonarow G.C., Masoudi F.A. Treatment and risk in heart failure: gaps in evidence or quality?. Circ. Cardiovasc. Qual. Outcomes 2010, 3:309-315.
6. Neely J.R., Morgan H.E. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu. Rev. Physiol. 1974, 36:413-459.
7. Neubauer S. The failing heart-an engine out of fuel. N. Engl. J. Med. 2007, 356:1140-1151.
8. Becker C., Sevilla L., Tomàs E., Palacin M., Zorzano A., Fischer Y. The endosomal compartment is an insulin-sensitive recruitment site for GLUT4 and GLUT1 glucose transporters in cardiac myocytes. Endocrinology 2001, 142:5267-5276.
9. Postic C., Leturque A., Printz R.L., Maulard P., Loizeau M., Granner D.K., Girard J. Development and regulation of glucose transporter and hexokinase expression in rat. Am. J. Physiol. Endocrinol. Metab. 1994, 266:E548-E559.
10. Santalucía T., Camps M., Castelló A., Muñoz P., Nuel A., Testar X., Palacin M., Zorzano A. Developmental regulation of GLUT-1 (erythroid/Hep G2) and GLUT-4 (muscle/fat) glucose transporter expression in rat heart, skeletal muscle, and brown adipose tissue. Endocrinology 1992, 130:837-846.
11. Depré C., Rider M.H., Hue L. Mechanisms of control of heart glycolysis. Eur. J. Biochem. 1998, 258:277-290.
12. Panchal A.R., Comte B., Huang H., Dudar B., Roth B., Chandler M., Des Rosiers C., Brunengraber H., Stanley W.C. Acute hibernation decreases myocardial pyruvate carboxylation and citrate release. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H1613-H1620.
13. Panchal A.R., Comte B., Huang H., Kerwin T., Darvish A., Rosiers C.D., Brunengraber H., Stanley W.C. Partitioning of pyruvate between oxidation and anaplerosis in swine hearts. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H2390-H2398.
14. Pound K.M., Sorokina N., Ballal K., Berkich D.A., Fasano M., LaNoue K.F., Taegtmeyer H., O'Donnell J.M., Lewandowski E.D. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content attenuating upregulated anaplerosis in hypertrophy. Circ. Res. 2009, 104:805-812.
15. Bricker D.K., Taylor E.B., Schell J.C., Orsak T., Boutron A., Chen Y.-C., Cox J.E., Cardon C.M., Van Vranken J.G., Dephoure N., Redin C., Boudina S., Gygi S.P., Brivet M., Thummel C.S., Rutter J. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 2012, 337:96-100.
16. Herzig S., Raemy E., Montessuit S., Veuthey J.-L., Zamboni N., Westermann B., Kunji E.R.S., Martinou J.-C. Identification and functional expression of the mitochondrial pyruvate carrier. Science 2012, 337:93-96.
17. Sugden M.C., Holness M.J. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E855-E862.
18. Kolobova E., Tuganova A., Boulatnikov I., Popov K.M. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem. J. 2001, 358:69.
19. Korotchkina L.G., Patel M.S. Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase. J. Biol. Chem. 2001, 276:37223-37229.
20. Holness M.J., Sugden M.C. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem. Soc. Trans. 2003, 31:1143-1151.
21. Spriet L.L., Heigenhauser G.J.F. Regulation of pyruvate dehydrogenase (PDH) activity in human skeletal muscle during exercise. Exerc. Sport Sci. Rev. 2002, 30:91-95.
22. Denton R.M., McCormack J.G., Rutter G.A., Burnett P., Edgell N.J., Moule S.K., Diggle T.A. The hormonal regulation of pyruvate dehydrogenase complex. Adv. Enzyme Regul. 1996, 36:183-198.
23. Jaswal J.S., Keung W., Wang W., Ussher J.R., Lopaschuk G.D. Targeting fatty acid and carbohydrate oxidation - a novel therapeutic intervention in the ischemic and failing heart. Biochim. Biophys. Acta Mol. Cell. Res. 2011, 1813:1333-1350.
24. Denton R.M., Randle P.J., Martin B.R. Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem. J. 1972, 128:161-163.
25. Su X., Abumrad N.A. Cellular fatty acid uptake: a pathway under construction. Trends Endocrinol. Metab. 2009, 20:72-77.
26. Koonen D.P.Y., Glatz J.F.C., Bonen A., Luiken J.J.F.P. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2005, 1736:163-180.
27. Nickerson J.G., Momken I., Benton C.R., Lally J., Holloway G.P., Han X.-X., Glatz J.F.C., Chabowski A., Luiken J.J.F.P., Bonen A. Protein-mediated fatty acid uptake: regulation by contraction, AMP-activated protein kinase, and endocrine signals. Appl. Physiol. Nutr. Metab. 2007, 32:865-873.
28. Harmon C.M., Abumrad N.A. Binding of sulfosuccinimidyl fatty acids to adipocyte membrane proteins: isolation and amino-terminal sequence of an 88-kD protein implicated in transport of long-chain fatty acids. J. Membr. Biol. 1993, 133:43-49.
29. Koonen D.P.Y., Glatz J.F.C., Bonen A., Luiken J.J.F.P. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2005, 1736:163-180.
30. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35years. Diabetes Metab. Rev. 1998, 14:263-283.
31. Lysiak W., Toth P.P., Suelter C.H., Bieber L.L. Quantitation of the efflux of acylcarnitines from rat heart, brain, and liver mitochondria. J. Biol. Chem. 1986, 261:13698-13703.
32. Al-Hesayen A., Azevedo E.R., Floras J.S., Hollingshead S., Lopaschuk G.D., Parker J.D. Selective versus nonselective B-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. Eur. J. Heart Fail. 2005, 7:618-623.
33. Dennis S.C., Gevers W., Opie L.H. Protons in ischemia: where do they come from; where do they go to?. J. Mol. Cell. Cardiol. 1991, 23:1077-1086.
34. Huang J.M., Xian H., Bacaner M. Long-chain fatty acids activate calcium channels in ventricular myocytes. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:6452.
35. Boehm E.A., Jones B.E., Radda G.K., Veech R.L., Clarke K. Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. Am. J. Physiol. Heart Circ. Physiol. 2001, 280:H977-H983.
36. Murray A.J., Anderson R.E., Watson G.C., Radda G.K., Clarke K. Uncoupling proteins in human heart. Lancet 2004, 364:1786-1788.
37. Seifert E.L., Bézaire V., Estey C., Harper M.-E. Essential role for uncoupling protein-3 in mitochondrial adaptation to fasting but not in fatty acid oxidation or fatty acid anion export. J. Biol. Chem. 2008, 283:25124-25131.
38. Klocke R., Tian W., Kuhlmann M.T., Nikol S. Surgical animal models of heart failure related to coronary heart disease. Cardiovasc. Res. 2007, 74:29-38.
39. Monnet E., Chachques J.C. Animal models of heart failure: what is new?. Ann. Thorac. Surg. 2005, 79:1445-1453.
40. 31P-SLOOP magnetic resonance spectroscopy. J. Am. Coll. Cardiol. 2002, 40:1267-1274.
41. 31P magnetic resonance spectroscopy. Lancet 1991, 338:973-976.
42. Nascimben L., Friedrich J., Liao R., Pauletto P., Pessina A.C., Ingwall J.S. Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. Circulation 1995, 91:1824-1833.
43. Tian R., Nascimben L., Kaddurah-Daouk R., Ingwall J.S. Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J. Mol. Cell. Cardiol. 1996, 28:755-765.
44. Neubauer S., Remkes H., Spindler M., Horn M., Wiesmann F., Prestle J., Walzel B., Ertl G., Hasenfuss G., Wallimann T. Downregulation of the Na+-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 1999, 100:1847-1850.
45. Kato T., Niizuma S., Inuzuka Y., Kawashima T., Okuda J., Tamaki Y., Iwanaga Y., Narazaki M., Matsuda T., Soga T., Kita T., Kimura T., Shioi T. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ. Heart Fail. 2010, 3:420-430.
46. Degens H., de Brouwer K.F.J., Gilde A.J., Lindhout M., Willemsen P.H.M., Janssen B.J., van der Vusse G.J., van Bilsen M. Cardiac fatty acid metabolism is preserved in the compensated hypertrophic rat heart. Basic Res. Cardiol. 2006, 101:17-26.
47. Lei B., Lionetti V., Young M.E., Chandler M.P., d' Agostino C., Kang E., Altarejos M., Matsuo K., Hintze T.H., Stanley W.C., Recchia F.A. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J. Mol. Cell. Cardiol. 2004, 36:567-576.
48. Liu Q., Docherty J.C., Rendell J.C.T., Clanachan A.S., Lopaschuk G.D. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J. Am. Coll. Cardiol. 2002, 39:718-725.
49. Van Bilsen M., Smeets P.J.H., Gilde A.J., Vusse G.J. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome?. Cardiovasc. Res. 2004, 61:218-226.
50. Allard M.F., Schonekess B.O., Henning S.L., English D.R., Lopaschuk G.D. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am. J. Physiol. Heart Circ. Physiol. 1994, 267:H742-H750.
51. Schönekess B.O., Allard M.F., Henning S.L., Wambolt R.B., Lopaschuk G.D. Contribution of glycogen and exogenous glucose to glucose metabolism during ischemia in the hypertrophied rat heart. Circ. Res. 1997, 81:540-549.
52. Wambolt R.B., Henning S.L., English D.R., Dyachkova Y., Lopaschuk G.D., Allard M.F. Glucose utilization and glycogen turnover are accelerated in hypertrophied rat hearts during severe low-flow ischemia. J. Mol. Cell. Cardiol. 1999, 31:493-502.
53. El Alaoui-Talibi Z., Guendouz A., Moravec M., Moravec J. Control of oxidative metabolism in volume-overloaded rat hearts: effect of propionyl-l-carnitine. Am. J. Physiol. Heart Circ. Physiol. 1997, 272:H1615-H1624.
54. el Alaoui-Talibi Z., Landormy S., Loireau A., Moravec J. Fatty acid oxidation and mechanical performance of volume-overloaded rat hearts. Am. J. Physiol. Heart Circ. Physiol. 1992, 262:H1068-H1074.
55. Aitman T.J., Glazier A.M., Wallace C.A., Cooper L.D., Norsworthy P.J., Wahid F.N., Al-Majali K.M., Trembling P.M., Mann C.J., Shoulders C.C., Graf D., Lezin E.S., Kurtz T.W., Kren V., Pravenec M., Ibrahimi A., Abumrad N.A., Stanton L.W., Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat. Genet. 1999, 21:76-83.
56. Vusse G.J., Van Bilsen M., Glatz J.F.C. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc. Res. 2000, 45:279-293.
57. Young M.E., Patil S., Ying J., Depre C., Ahuja H.S., Shipley G.L., Stepkowski S.M., Davies P.J.A., Taegtmeyer H. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor A in the adult rodent heart. FASEB J. 2001, 15:833-845.
58. Morissette M.R., Howes A.L., Zhang T., Heller Brown J. Upregulation of GLUT1 expression is necessary for hypertrophy and survival of neonatal rat cardiomyocytes. J. Mol. Cell. Cardiol. 2003, 35:1217-1227.
59. Keller A., Rouzeau J.D., Farhadian F., Wisnewsky C., Marotte F., Lamande N., Samuel J.L., Schwartz K., Lazar M., Lucas M. Differential expression of alpha- and beta-enolase genes during rat heart development and hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 1995, 269:H1843-H1851.
60. de Brouwer K.F.J., Degens H., Aartsen W.M., Lindhout M., Bitsch N.J.J.E., Gilde A.J., Willemsen P.H.M., Janssen B.J.A., van der Vusse G.J., van Bilsen M. Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice. J. Mol. Cell. Cardiol. 2006, 40:838-845.
61. O'Donnell J.M., Fields A.D., Sorokina N., Lewandowski E.D. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J. Mol. Cell. Cardiol. 2008, 44:315-322.
62. Bugger H., Schwarzer M., Chen D., Schrepper A., Amorim P.A., Schoepe M., Nguyen T.D., Mohr F.W., Khalimonchuk O., Weimer B.C., Doenst T. Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovasc. Res. 2010, 85:376-384.
63. Doenst T., Pytel G., Schrepper A., Amorim P., Färber G., Shingu Y., Mohr F.W., Schwarzer M. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc. Res. 2010, 86:461-470.
64. Osorio J.C., Stanley W.C., Linke A., Castellari M., Diep Q.N., Panchal A.R., Hintze T.H., Lopaschuk G.D., Recchia F.A. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-A in pacing-induced heart failure. Circulation 2002, 106:606-612.
65. Qanud K., Mamdani M., Pepe M., Khairallah R.J., Gravel J., Lei B., Gupte S.A., Sharov V.G., Sabbah H.N., Stanley W.C., Recchia F.A. Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2098-H2105.
66. Neglia D., De Caterina A., Marraccini P., Natali A., Ciardetti M., Vecoli C., Gastaldelli A., Ciociaro D., Pellegrini P., Testa R., Menichetti L., L'Abbate A., Stanley W.C., Recchia F.A. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H3270-H3278.
67. Tuunanen H., Engblom E., Naum A., Någren K., Hesse B., Airaksinen K.E.J., Nuutila P., Iozzo P., Ukkonen H., Opie L.H., Knuuti J. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006, 114:2130-2137.
68. Panchal A.R., Stanley W.C., Kerner J., Sabbah H.N. Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J. Card. Fail. 1998, 4:121-126.
69. Podbregar M., Voga G. Effect of selective and nonselective β-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J. Card. Fail. 2002, 8:369-378.
70. Eichhorn E.J., Bedotto J.B., Malloy C.R., Hatfield B.A., Deitchman D., Brown M., Willard J.E., Grayburn P.A. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990, 82:473-483.
71. Eichhorn E.J., Heesch C.M., Barnett J.H., Alvarez L.G., Fass S.M., Grayburn P.A., Hatfield B.A., Marcoux L.G., Malloy C.R. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 1994, 24:1310-1320.
72. Wallhaus T.R., Taylor M., DeGrado T.R., Russell D.C., Stanko P., Nickles R.J., Stone C.K. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001, 103:2441-2446.
73. Gilde A.J., Van Der Lee K.A.J.M., Willemsen P.H.M., Chinetti G., Van Der Leij F.R., Van Der Vusse G.J., Staels B., Van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) A and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. 2003, 92:518-524.
74. Hondares E., Pineda-Torra I., Iglesias R., Staels B., Villarroya F., Giralt M. PPARδ, but not PPARα, activates PGC-1α gene transcription in muscle. Biochem. Biophys. Res. Commun. 2007, 354:1021-1027.
75. Cheng L., Ding G., Qin Q., Huang Y., Lewis W., He N., Evans R.M., Schneider M.D., Brako F.A., Xiao Y., Chen Y.E., Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 2004, 10:1245.
76. Pellieux C., Montessuit C., Papageorgiou I., Lerch R. Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-A. Cardiovasc. Res. 2009, 82:341-350.
77. Planavila A., Laguna J.C., Vázquez-Carrera M. Nuclear factor-κB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J. Biol. Chem. 2005, 280:17464-17471.
78. Burkart E.M., Sambandam N., Han X., Gross R.W., Courtois M., Gierasch C.M., Shoghi K., Welch M.J., Kelly D.P. Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Invest. 2007, 117:3930-3939.
79. Sidell R.J., Cole M.A., Draper N.J., Desrois M., Buckingham R.E., Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 2002, 51:1110-1117.
80. Zhu P., Lu L., Xu Y., Schwartz G.G. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000, 101:1165-1171.
81. Yue T.-L., Bao W., Gu J.-L., Cui J., Tao L., Ma X.-L., Ohlstein E.H., Jucker B.M. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54:554-562.
82. Lindenfeld J., Masoudi F.A. Fluid retention with thiazolidinediones: does the mechanism influence the outcome?. J. Am. Coll. Cardiol. 2007, 49:1705-1707.
83. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefèbvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Korányi L., Laakso M., Mokáň M., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
84. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356:2457-2471.
85. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 2010, 170:1191-1201.
86. Komajda M., McMurray J.J.V., Beck-Nielsen H., Gomis R., Hanefeld M., Pocock S.J., Curtis P.S., Jones N.P., Home P.D. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur. Heart J. 2010, 31:824-831.
87. Schoonjans K., Staels B., Grimaldi P., Auwerx J. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur. J. Biochem. 1993, 216:615-622.
88. Cook W.S., Yeldandi A.V., Rao M.S., Hashimoto T., Reddy J.K. Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha. Biochem. Biophys. Res. Commun. 2000, 278:250-257.
89. Yue T., Bao W., Jucker B.M., Gu J., Romanic A.M., Brown P.J., Cui J., Thudium D.T., Boyce R., Burns-Kurtis C.L., Mirabile R.C., Aravindhan K., Ohlstein E.H. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 2003, 108:2393-2399.
90. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 1999, 341:410-418.
91. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., Faas F.H., Anderson J.W. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. 2002, 162:2597-2604.
92. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesäniemi Y.A., Sullivan D., Hunt D., Colman P., D' Emden M., Ehnholm C., Whiting M., Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
93. Reaven G.M., Chang H., Hoffman B.B. Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes. Diabetes 1988, 37:28-32.
94. ®. Horm. Metab. Res. 2007, 27:515-522.
95. Wall S.R., Lopaschuk G.D. Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats. Biochim. Biophys. Acta 1989, 1006:97-103.
96. Turcani M., Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 1997, 96:3681-3686.
97. Rupp H., Vetter R. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure. Br. J. Pharmacol. 2000, 131:1748-1756.
98. Schmidt-Schweda S., Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin. Sci. 2000, 99:27-35.
99. Holubarsch C.J.F., Rohrbach M., Karrasch M., Boehm E., Polonski L., Ponikowski P., Rhein S. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin. Sci. 2007, 113:205-212.
100. Lee L., Campbell R., Scheuermann-Freestone M., Taylor R., Gunaruwan P., Williams L., Ashrafian H., Horowitz J., Fraser A.G., Clarke K., Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005, 112:3280-3288.
101. Abozguia K., Elliott P., McKenna W., Phan T.T., Nallur-Shivu G., Ahmed I., Maher A.R., Kaur K., Taylor J., Henning A., Ashrafian H., Watkins H., Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010, 122:1562-1569.
102. Cheng J.-F., Chen M., Wallace D., Tith S., Haramura M., Liu B., Mak C.C., Arrhenius T., Reily S., Brown S., Thorn V., Harmon C., Barr R., Dyck J.R.B., Lopaschuk G.D., Nadzan A.M. Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J. Med. Chem. 2006, 49:1517-1525.
103. Cheng J.-F., Huang Y., Penuliar R., Nishimoto M., Liu L., Arrhenius T., Yang G., O'leary E., Barbosa M., Barr R., Dyck J.R.B., Lopaschuk G.D., Nadzan A.M. Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents. J. Med. Chem. 2006, 49:4055-4058.
104. Dyck J.R.B., Cheng J.-F., Stanley W.C., Barr R., Chandler M.P., Brown S., Wallace D., Arrhenius T., Harmon C., Yang G., Nadzan A.M., Lopaschuk G.D. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ. Res. 2004, 94:e78-e84.
105. Stanley W.C., Morgan E.E., Huang H., McElfresh T.A., Sterk J.P., Okere I.C., Chandler M.P., Cheng J., Dyck J.R.B., Lopaschuk G.D. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H2304-H2309.
106. Cheng J.-F., Mak C.C., Huang Y., Penuliar R., Nishimoto M., Zhang L., Chen M., Wallace D., Arrhenius T., Chu D., Yang G., Barbosa M., Barr R., Dyck J.R.B., Lopaschuk G.D., Nadzan A.M. Heteroaryl substituted bis-trifluoromethyl carbinols as malonyl-CoA decarboxylase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16:3484-3488.
107. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2000, 86:580-588.
108. Lopaschuk G.D., Barr R., Thomas P.D., Dyck J.R.B. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ. Res. 2003, 93:e33-e37.
109. MacInnes A., Fairman D.A., Binding P., Rhodes J. Ann, Wyatt M.J., Phelan A., Haddock P.S., Karran E.H. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2003, 93:e26-e32.
110. Saeedi R., Grist M., Wambolt R.B., Bescond-Jacquet A., Lucien A., Allard M.F. Trimetazidine normalizes postischemic function of hypertrophied rat hearts. J. Pharmacol. Exp. Ther. 2005, 314:446-454.
111. Fragasso G., Perseghin G., De Cobelli F., Esposito A., Palloshi A., Lattuada G., Scifo P., Calori G., Del Maschio A., Margonato A. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur. Heart J. 2006, 27:942-948.
112. Fragasso G., Palloshi A., Puccetti P., Silipigni C., Rossodivita A., Pala M., Calori G., Alfieri O., Margonato A. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J. Am. Coll. Cardiol. 2006, 48:992-998.
113. Tuunanen H., Engblom E., Naum A., Någren K., Scheinin M., Hesse B., Juhani Airaksinen K.E., Nuutila P., Iozzo P., Ukkonen H., Opie L.H., Knuuti J. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008, 118:1250-1258.
114. McCormack J.G., Baracos V.E., Barr R., Lopaschuk G.D. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. J. Appl. Physiol. 1996, 81:905-910.
115. McCormack J.G., Barr R.L., Wolff A.A., Lopaschuk G.D. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996, 93:135-142.
116. Clarke B., Spedding M., Patmore L., McCormack J.G. Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br. J. Pharmacol. 1993, 109:748-750.
117. Clarke B., Wyatt K.M., McCormack J.G. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J. Mol. Cell. Cardiol. 1996, 28:341-350.
118. Lovelock J.D., Monasky M.M., Jeong E.-M., Lardin H.A., Liu H., Patel B.G., Taglieri D.M., Gu L., Kumar P., Pokhrel N., Zeng D., Belardinelli L., Sorescu D., Solaro R.J., Dudley S.C. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ. Res. 2012, 110:841-850.
119. Wyatt K.M., Skene C., Veitch K., Hue L., McCormack J.G. The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochem. Pharmacol. 1995, 50:1599-1606.
120. Sabbah H.N., Chandler M.P., Mishima T., Suzuki G., Chaudhry P., Nass O., Biesiadecki B.J., Blackburn B., Wolff A., Stanley W.C. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J. Card. Fail. 2002, 8:416-422.
121. Rastogi S., Sharov V.G., Mishra S., Gupta R.C., Blackburn B., Belardinelli L., Stanley W.C., Sabbah H.N. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2149-H2155.
122. Jacobshagen C., Belardinelli L., Hasenfuss G., Maier L.S. Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF Study. Clin. Cardiol. 2011, 34:426-432.
123. Liu B., Clanachan A.S., Schulz R., Lopaschuk G.D. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ. Res. 1996, 79:940-948.
124. Aicher T.D., Anderson R.C., Bebernitz G.R., Coppola G.M., Jewell C.F., Knorr D.C., Liu C., Sperbeck D.M., Brand L.J., Strohschein R.J., Gao J., Vinluan C.C., Shetty S.S., Dragland C., Kaplan E.L., DelGrande D., Islam A., Liu X., Lozito R.J., Maniara W.M., et al. (R)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionamides are orally active inhibitors of pyruvate dehydrogenase kinase. J. Med. Chem. 1999, 42:2741-2746.
125. Bebernitz G.R., Aicher T.D., Stanton J.L., Gao J., Shetty S.S., Knorr D.C., Strohschein R.J., Tan J., Brand L.J., Liu C., Wang W.H., Vinluan C.C., Kaplan E.L., Dragland C.J., DelGrande D., Islam A., Lozito R.J., Liu X., Maniara W.M., Mann W.R. Anilides of (R)-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase. J. Med. Chem. 2000, 43:2248-2257.
126. Morrell J.A., Orme J., Butlin R.J., Roche T.E., Mayers R.M., Kilgour E. AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2. Biochem. Soc. Trans. 2003, 31:1168-1170.
127. Labarthe F., Gélinas R., Des Rosiers C. Medium-chain fatty acids as metabolic therapy in cardiac disease. Cardiovasc. Drugs Ther. 2008, 22:97-106.
128. Myrmel T., Forsdahl K., Larsen T.S. Triacylglycerol metabolism in hypoxic, glucose-deprived rat cardiomyocytes. J. Mol. Cell. Cardiol. 1992, 24:855-868.
129. Hajri T., Ibrahimi A., Coburn C.T., Knapp F.F., Kurtz T., Pravenec M., Abumrad N.A. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J. Biol. Chem. 2001, 276:23661-23666.
130. Iemitsu M., Shimojo N., Maeda S., Irukayama-Tomobe Y., Sakai S., Ohkubo T., Tanaka Y., Miyauchi T. The benefit of medium-chain triglyceride therapy on the cardiac function of SHRs is associated with a reversal of metabolic and signaling alterations. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H136-H144.
131. Shimojo N., Miyauchi T., Iemitsu M., Irukayama-Tomobe Y., Maeda S., Ohkubo T., Tanaka Y., Goto K., Yamaguchi I. Effects of medium-chain triglyceride (MCT) application to SHR on cardiac function, hypertrophy and expression of endothelin-1 mRNA and other genes. J. Cardiovasc. Pharmacol. 2004, 44(Suppl. 1):S181-S185.
132. Lopaschuk G.D., Folmes C.D.L., Stanley W.C. Cardiac energy metabolism in obesity. Circ. Res. 2007, 101:335-347.
133. Finck B.N., Han X., Courtois M., Aimond F., Nerbonne J.M., Kovacs A., Gross R.W., Kelly D.P. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1226-1231.
134. McGarry J.D., Dobbins R.L. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999, 42:128-138.
135. Schaffer J.E. Lipotoxicity: when tissues overeat. Curr. Opin. Lipidol. 2003, 14:281-287.
136. Unger R.H. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003, 144:5159-5165.
137. Yagyu H., Chen G., Yokoyama M., Hirata K., Augustus A., Kako Y., Seo T., Hu Y., Lutz E.P., Merkel M., Bensadoun A., Homma S., Goldberg I.J. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J. Clin. Invest. 2003, 111:419-426.
138. Yokoyama M., Yagyu H., Hu Y., Seo T., Hirata K., Homma S., Goldberg I.J. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J. Biol. Chem. 2004, 279:4204-4211.
139. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., Orci L., Unger R.H. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:1784-1789.
140. Saddik M., Gamble J., Witters L.A., Lopaschuk G.D. Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J. Biol. Chem. 1993, 268:25836-25845.
141. Ussher J.R., Koves T.R., Jaswal J.S., Zhang L., Ilkayeva O., Dyck J.R.B., Muoio D.M., Lopaschuk G.D. Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes 2009, 58:1766-1775.
142. Okere I.C., Chandler M.P., McElfresh T.A., Rennison J.H., Kung T.A., Hoit B.D., Ernsberger P., Young M.E., Stanley W.C. Carnitine palmitoyl transferase-I inhibition is not associated with cardiac hypertrophy in rats fed a high-fat diet. Clin. Exp. Pharmacol. Physiol. 2007, 34:113-119.
143. Kolwicz S.C., Olson D.P., Marney L.C., Garcia-Menendez L., Synovec R.E., Tian R. Cardiac-specific deletion of acetyl CoA carboxylase 2 (ACC2) prevents metabolic remodeling during pressure-overload hypertrophy. Circ. Res. 2012, 366:1279-1289.